Medical Devices France

France Pharmacogenomic Testing Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

France Pharmacogenomic Testing Market Industry Trends and Forecast to 2034: Segmented by (Test, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

France · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $84.8 Mn Placeholder estimate
Estimate 2025 $92.2 Mn 2.9% of the global market
Projected 2034 $195.3 Mn 111.9% Adds $103.1 Mn over 9 forecast years
CAGR 2025–2034 8.7% Faster than 57% of 173 Medical Devices markets here
Key players 5
  • France is 2.93% of the global market.
  • In Europe, the largest is Germany at $98.1 Mn.
  • Fastest growing: Russia at 10.3% a year.
  • France ranks 2nd of 6 by size in Europe.

Market size projection

France

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$103.1 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Pharmacogenomic Testing Market market size by year, France
YearMarket sizeChange that yearSince 2025
2024 (estimate) $84.8 Mn — —
2025 (base) $92.2 Mn +$7.4 Mn —
2026 (forecast) $100.2 Mn +$8.0 Mn +8.7%
2027 (forecast) $108.9 Mn +$8.7 Mn +18.2%
2028 (forecast) $118.4 Mn +$9.5 Mn +28.4%
2029 (forecast) $128.7 Mn +$10.3 Mn +39.6%
2030 (forecast) $139.9 Mn +$11.2 Mn +51.8%
2031 (forecast) $152.0 Mn +$12.2 Mn +65%
2032 (forecast) $165.3 Mn +$13.2 Mn +79.3%
2033 (forecast) $179.6 Mn +$14.4 Mn +94.9%
2034 (forecast) $195.3 Mn +$15.6 Mn +111.9%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $3.15 Bn
  2. North America $1.66 Bn
  3. US $1.27 Bn
  4. Europe $657.7 Mn
  5. APAC $591.4 Mn
  6. Canada $238.1 Mn
  7. Japan $225.2 Mn
  8. China $224.6 Mn
  9. Latin America $163.4 Mn
  10. Middle East $120.9 Mn
  11. Germany $98.1 Mn
  12. France (this report) $92.2 Mn
  13. Brazil $87.5 Mn
  14. UK $82.5 Mn
  15. Italy $72.6 Mn
  16. India $67.4 Mn
  17. Saudi Arabia $61.2 Mn
  18. Ecuador $59.7 Mn
  19. Africa $55.7 Mn
  20. Spain $52.6 Mn
  21. Mexico $52.1 Mn
  22. Australia $36.2 Mn
  23. New Zealand $33.0 Mn
  24. Russia $31.8 Mn
  25. South Africa $20.7 Mn
  26. UAE $15.7 Mn
  27. Egypt $8.8 Mn
  28. Philippines $7.7 Mn
  29. Malaysia $5.7 Mn
  30. Hong Kong $5.1 Mn
  31. Thailand $3.8 Mn
  32. Singapore $3.7 Mn
  33. Kenya $2.2 Mn

Report snapshot

France Pharmacogenomic Testing Market Analysis at a glance
Market size, 2025$92.2 Mn placeholder estimate
Forecast, 2034$195.3 Mn placeholder estimate
Growth (CAGR), 2025–20348.7% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTest, application and end user (see all)
Key playersMyriad Genetics, Inc., OneOme, Genomind, Thermo Fisher Scientific Inc., RPRD Diagnostics (see all)
Regulator in FranceANSMSource: ANSM, French medicines agency. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The France Pharmacogenomic Testing Market Analysis Executive Summary

Pharmacogenomic testing checks a person's genes to predict how they will respond to medicines, helping choose the right drug and dose.

Key segments of the pharmacogenomic Testing market include test (Multi-Gene Panels and Single-Gene Tests) and application (Psychiatry, Cardiology and Oncology).

Bar chart: France Pharmacogenomic Testing market size, 2024–2034, placeholder estimates. $84.8 Mn in 2024, $92.2 Mn in 2025 and $195.3 Mn in 2034, 8.7% CAGR.
France Pharmacogenomic Testing market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

France Pharmacogenomic Testing Market Dynamics

Market Growth Drivers

The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the pharmacogenomic Testing market.

Opportunity

Routine use of genomics in screening, pharmacy and primary care gives the pharmacogenomic Testing market large room to grow.

Market Restraints

Data privacy concerns, limited reimbursement for some tests, shortages of genetic counsellors and complex data analysis hold back the pharmacogenomic Testing market.

Competitive Landscape for Pharmacogenomic Testing Market in France

The pharmacogenomic Testing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Pharmacogenomic Testing Market in France

Pharmacogenomic Testing in France: rules and payment

Medical devices need CE marking under the EU Medical Device Regulation (MDR); ANSM, the French medicines agency, monitors their safety in France.⁠[1] National health insurance (Assurance Maladie) pays back part of most care costs, and the HAS, the French National Authority for Health, advises on what it should cover.⁠[2]

[1] ANSM, French medicines agency. Checked 14 Nov 2026.

[2] Assurance Maladie (ameli.fr). Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how pharmacogenomic Testing products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in France.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Pharmacogenomic Testing right now, from free public sources.

Latest research 369 papers since 2021 (worldwide)

  1. Mitochondrial mutation m.1555A>G and aminoglycoside-induced hearing loss in neonates: an integrative review. Frontiers in pediatrics, 2026
  2. Genetic determinants of direct oral anticoagulant (DOAC) response: evidence, limitations and barriers to clinical implementation. Expert review of clinical pharmacology, 2026
  3. Advancing Precision Therapeutics in Older Adults: A Scoping Review of Pharmacogenomic Service Models. Clinical pharmacology and therapeutics, 2026
  4. Implementation of Pharmacogenomics in Pediatric-Focused Institutions Within the Pharmacogenomics Global Research Network. Clinical pharmacology and therapeutics, 2026
  5. Genotype-derived interpretive categories of drug response in 908 pharmacogenomic reports from Chinese patients with type 2 diabetes: A retrospective single-centre study. PloS one, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Pharmacogenomic Testing in context

France compared

  • Health spending per person: 5,327 US$ per person (2024). World: 1,317 US$ per person (2023). 3rd highest of the 6 countries we cover in Europe.[1]
  • Doctors: 3.28 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 6th highest of the 6 countries we cover in Europe.[2]
  • People aged 65 and over: 22.5% of people (2025). World: 10.4% of people (2025). 3rd highest of the 6 countries we cover in Europe.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Pharmacogenomic Testing market in France?
Placeholder estimate: about $92.2 Mn in 2025, rising to about $195.3 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Pharmacogenomic Testing market in France growing?
Placeholder estimate: about 8.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Pharmacogenomic Testing market report cover?
The report splits the market by test (Multi-Gene Panels, Single-Gene Tests), application (Psychiatry, Cardiology, Oncology, Pain Management) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Pharmacogenomic Testing market?
Key players include Myriad Genetics, Inc., OneOme, Genomind, Thermo Fisher Scientific Inc. and RPRD Diagnostics.
What is driving the Pharmacogenomic Testing market?
The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the pharmacogenomic Testing market.
Who regulates Pharmacogenomic Testing in France?
Medical devices need CE marking under the EU Medical Device Regulation (MDR); ANSM, the French medicines agency, monitors their safety in France. Source: ANSM, French medicines agency. Checked 14 Nov 2026.
How is healthcare paid for in France?
National health insurance (Assurance Maladie) pays back part of most care costs, and the HAS, the French National Authority for Health, advises on what it should cover. Source: Assurance Maladie (ameli.fr). Checked 14 Nov 2026.
How much research is published on Pharmacogenomic Testing?
PubMed lists 369 papers on Pharmacogenomic Testing added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Pharmacogenomic Testing in France? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard

From our blog

Dermatology Diagnostics: AI and Skin HealthSkin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions… Molecular Point-of-Care Tests: Lab Accuracy, Clinic SpeedTB killed 1.23 million people in 2024. WHO now recommends rapid molecular tests first, bringing lab-grade… Healthcare In-Vitro Diagnostics: What Comes After COVIDCOVID-19 testing created a huge, short-lived spike. Long-term demand for in-vitro diagnostics now comes from…
Back to Catalogue
Keep exploring

Related Medical Devices reports in France

See all
Same topic, other categories

Related on genomics and diagnostics and lab testing

See the topic